News Releases Keyword Search Year None202420232022202120202019201820172016 Oct-31-2019 Oncternal Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update Oct-03-2019 Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma Sep-17-2019 Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Children’s Oncology Group Meeting Sep-09-2019 Oncternal Further Expands Executive Team; Appoints Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer Aug-28-2019 Oncternal Expands Leadership Team with Appointment of Frank Hsu, M.D., as Chief Medical Officer, and Rajesh Krishnan, Ph.D., as Senior VP CMC and Manufacturing Aug-08-2019 Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update Aug-06-2019 Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib Aug-01-2019 Oncternal Therapeutics to Report Second Quarter 2019 Financial Results and Provide Business Update Jun-10-2019 Oncternal Therapeutics Completes Reverse Merger with GTx, Inc. Jun-03-2019 Oncternal Therapeutics Announces Updated Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib Pagination First page « first Previous page ‹ previous … Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Current page 15 Page 16 Page 17 Next page next › Last page last »